Skip to search formSkip to main contentSkip to account menu

dehydroxymethylepoxyquinomicin

Known as: DHMEQ cpd 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

BenzamidesCyclohexanones

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Possible role of peritoneal NF-κB in peripheral inflammation and cancer: lessons from the inhibitor DHMEQ.
  • K. Umezawa
  • Biomedicine & pharmacotherapy = Biomedecine…
  • 2011
  • Corpus ID: 30094626
2008
2008
Identification of the RelA domain responsible for action of a new NF-kappaB inhibitor DHMEQ.
Review
2007
Review
2007
Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent.
Highly Cited
2007
Highly Cited
2007
Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
PURPOSE To investigate the involvement of the renin-angiotensin system (RAS) and the nuclear factor (NF)-kappaB pathway with… 
Highly Cited
2007
Highly Cited
2007
Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
Immunotherapy with rituximab (chimeric anti-CD20 monoclonal antibody, Rituxan), alone or in conjunction with chemotherapy, has… 
Highly Cited
2006
Highly Cited
2006
BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation.
The BRAFV600E mutation is closely linked to tumorigenesis and malignant phenotype of papillary thyroid cancer. Signaling pathways… 
Highly Cited
2005
Highly Cited
2005
Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
We previously designed and synthesized the new nuclear factor kappaB (NF-kappaB) inhibitor dehydroxymethylepoxyquinomicin (DHMEQ… 
Highly Cited
2005
Highly Cited
2005
In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia.
Adult T-cell leukemia (ATL) is an aggressive neoplasm caused by human T-cell leukemia virus type I (HTLV-I). The nuclear… 
Highly Cited
2004
Highly Cited
2004
Induction of Thyroid Cancer Cell Apoptosis by a Novel Nuclear Factor κB Inhibitor, Dehydroxymethylepoxyquinomicin
Purpose: The objective of the study was to determine the effects of a novel selective nuclear factor κB (NF-κB) inhibitor… 
Highly Cited
2002
Highly Cited
2002
Inhibition of tumor necrosis factor-alpha -induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin.
We previously designed and synthesized an NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), that showed anti… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)